Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Type of study
Year range
1.
The Japanese Journal of Rehabilitation Medicine ; : 503-510, 2022.
Article in Japanese | WPRIM | ID: wpr-936696

ABSTRACT

Objective:To clarify the effect of exclusion items on the KRW achievement index (KRW-AI) in the outcome evaluation of a convalescent rehabilitation ward.Methods:The subjects were 812 inpatients in a convalescent rehabilitation ward. The objective variable was the KRW-AI of 40 or less, and the explanatory variables were the items excluded from the KRW-AI and their combination for a total of eight categories, such as (1) low motor FIM, (2) high motor FIM, (3) low cognitive FIM, (4) elderly, (5) (1)+(3), (6) (1)+(4), (7) (3)+(4), (8) (1)+(3)+(4). The adjusted variables were sex, rehabilitation calculation category, and time from onset to admission to the ward. Poisson regression analysis was performed. The Incidence Rate Ratio (IRR) and 95% confidence interval (CI) were calculated.Results:Five of the eight exclusion categories were significantly associated with low-KRW-AI scores. The highest IRR was 2.29 (95% CI:1.41-3.69, p<0.001) for (2).Conclusion:High motor FIM are associated with a higher relative risk of falling below the KRW-AI of 40. Conversely, being older and the presence of cognitive disorder did not interfere with low-KRW-AI scores.

2.
The Japanese Journal of Rehabilitation Medicine ; : 21016-2022.
Article in Japanese | WPRIM | ID: wpr-924599

ABSTRACT

Objective:To clarify the effect of exclusion items on the KRW achievement index (KRW-AI) in the outcome evaluation of a convalescent rehabilitation ward.Methods:The subjects were 812 inpatients in a convalescent rehabilitation ward. The objective variable was the KRW-AI of 40 or less, and the explanatory variables were the items excluded from the KRW-AI and their combination for a total of eight categories, such as (1) low motor FIM, (2) high motor FIM, (3) low cognitive FIM, (4) elderly, (5) (1)+(3), (6) (1)+(4), (7) (3)+(4), (8) (1)+(3)+(4). The adjusted variables were sex, rehabilitation calculation category, and time from onset to admission to the ward. Poisson regression analysis was performed. The Incidence Rate Ratio (IRR) and 95% confidence interval (CI) were calculated.Results:Five of the eight exclusion categories were significantly associated with low-KRW-AI scores. The highest IRR was 2.29 (95% CI:1.41-3.69, p<0.001) for (2).Conclusion:High motor FIM are associated with a higher relative risk of falling below the KRW-AI of 40. Conversely, being older and the presence of cognitive disorder did not interfere with low-KRW-AI scores.

3.
Yonsei Medical Journal ; : 1031-1034, 2011.
Article in English | WPRIM | ID: wpr-116319

ABSTRACT

High-dose methotrexate-based chemotherapy has extended survival in patients with primary central nervous system lymphoma (PCNSL). However, although salvage treatment is necessary in recurrent and refractory PCNSL, this has not been standardized. We herein describe the efficacy of a combination of rituximab and temozolomide (TMZ) in two consecutive patients with recurrent and refractory PCNSL. Based on the immunohistochemical study, case 1 had a non-germinal center B-cell-like (non-GCB) subtype, was positive for bcl-2 and negative for O6-methylguanine-DNA methyltransferase (MGMT). Case 2 was GCB subtype, bcl-2-, and MGMT+. Because of the positive expression of MGMT, interferon-beta was additionally given in case 2. Complete responses and partial responses were obtained after the third and fourth cycles of combination therapy, respectively. This was maintained for 12 months, with acceptable toxicity. The combination of rituximab and TMZ was effective in tumors with different immunohistochemical profiles. This combination therapy warrants further study in a larger population.


Subject(s)
Aged , Humans , Male , Middle Aged , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Agents/therapeutic use , Central Nervous System Neoplasms/drug therapy , Dacarbazine/analogs & derivatives , Drug Therapy, Combination/methods , Lymphoma/drug therapy , Neoplasm Recurrence, Local/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL